Group 1: Clinical Trials and Collaborations - The company Henlius (Shanghai Henlius Biopharmaceutical) is collaborating with Carolyn Bertozzi's team to initiate the first human clinical trial next year [2][7] - The therapy being developed is a dual-function sialidase fusion protein therapy aimed at targeting cancer cells [7] Group 2: Scientific Breakthroughs - Carolyn Bertozzi has made significant breakthroughs in bioorthogonal chemistry, which allows for the tracking and modification of specific biomolecules without disrupting natural biological processes [6] - The developed antibody drug targets sialic acid on cancer cells, enhancing the immune system's ability to recognize and eliminate these cells [5][6] Group 3: Impact on Cancer Treatment - The immune therapy developed by Bertozzi's team has the potential to cure certain types of cancer, such as melanoma and lung cancer, which have higher mutation rates and more receptors on their surface [6] - The advancements in cancer immunotherapy are being referred to as a "penicillin moment" for cancer treatment, indicating a significant breakthrough in the field [2]
爱玩摇滚的诺奖得主上海发声：正和中国公司合作癌症免疫治疗